
Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

